Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Completed1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

completed133%
terminated133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

NCT01143389
terminatednot_applicable

Cross Linking for Treatment of Corneal Infection

NCT00912509
unknownphase_2

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298

Clinical Trials (3)

Showing 3 of 3 trials
NCT01143389Phase 2

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

Completed
NCT00912509Not Applicable

Cross Linking for Treatment of Corneal Infection

Terminated
NCT01325298Phase 2

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3